In a regulatory filing, Verve Therapeutics disclosed that its COO/General Counsel Andrew Ashe bought 76K shares of common stock on May 14th in a total transaction of $475.8K. Shares of Verve Therapeutics are up 4.3% afterhours at $6.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics’ Financial Outlook Threatened by CRISPR Patent Disputes
- Verve Therapeutics reports Q1 EPS (59c), consensus (71c)
- Verve Therapeutics announces dosing of first patient in VERVE-102 trial
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics initiated with a Buy at H.C. Wainwright